MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Iovance Biotherapeutics Inc

Closed

SectorHealthcare

3 -7.69

Overview

Share price change

24h

Current

Min

2.95

Max

3.25

Key metrics

By Trading Economics

Income

5M

-79M

Sales

15M

74M

EPS

-0.26

Profit margin

-106.602

Employees

838

EBITDA

14M

-75M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+510.15% upside

Dividends

By Dow Jones

Next Earnings

8 maj 2025

Market Stats

By TradingEconomics

Market Cap

-524M

1.2B

Previous open

10.69

Previous close

3

News Sentiment

By Acuity

50%

50%

167 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Iovance Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 kwi 2025, 22:38 UTC

Hot Stocks

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4 kwi 2025, 21:53 UTC

Market Talk

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 kwi 2025, 21:44 UTC

Top News
Acquisitions, Mergers, Takeovers

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 kwi 2025, 21:00 UTC

Top News

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 kwi 2025, 20:52 UTC

Market Talk

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 kwi 2025, 20:52 UTC

Top News

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 kwi 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 kwi 2025, 20:48 UTC

Top News

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 kwi 2025, 20:45 UTC

Top News

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 kwi 2025, 20:32 UTC

Top News

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 kwi 2025, 20:21 UTC

Top News

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 kwi 2025, 20:00 UTC

Top News

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 kwi 2025, 19:51 UTC

Market Talk

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 kwi 2025, 19:37 UTC

Top News

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 kwi 2025, 19:32 UTC

Market Talk

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 kwi 2025, 19:28 UTC

Top News

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 kwi 2025, 19:15 UTC

Market Talk

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 kwi 2025, 19:12 UTC

Top News

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 kwi 2025, 19:11 UTC

Market Talk

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 kwi 2025, 19:09 UTC

Market Talk

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 kwi 2025, 19:09 UTC

Top News

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 kwi 2025, 19:00 UTC

Market Talk

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 kwi 2025, 18:53 UTC

Market Talk

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 kwi 2025, 18:51 UTC

Market Talk

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 kwi 2025, 18:44 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 kwi 2025, 18:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 kwi 2025, 18:44 UTC

Market Talk

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4 kwi 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4 kwi 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4 kwi 2025, 18:39 UTC

Market Talk

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Peer Comparison

Price change

Iovance Biotherapeutics Inc Forecast

Price Target

By TipRanks

510.15% upside

12 Months Forecast

Average 19.83 USD  510.15%

High 32 USD

Low 6 USD

Based on 13 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

N/A / 3.42Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

No Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

167 / 386 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.